Agenus Inc. (NASDAQ:AGEN - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.08 and traded as high as $4.84. Agenus shares last traded at $4.80, with a volume of 750,338 shares.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on AGEN shares. HC Wainwright upgraded Agenus from a "neutral" rating to a "buy" rating and set a $25.00 price target on the stock in a research note on Wednesday, June 4th. Robert W. Baird increased their price objective on shares of Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a research report on Wednesday, June 4th. B. Riley restated a "buy" rating on shares of Agenus in a research note on Monday, April 21st. Finally, Wall Street Zen upgraded shares of Agenus from a "strong sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $14.00.
View Our Latest Stock Report on AGEN
Agenus Price Performance
The stock's 50-day moving average price is $3.81 and its 200-day moving average price is $3.10. The company has a market cap of $135.18 million, a P/E ratio of -0.57 and a beta of 1.43.
Agenus (NASDAQ:AGEN - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to analyst estimates of $26.38 million. As a group, analysts expect that Agenus Inc. will post -12.55 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the stock. Corton Capital Inc. bought a new position in Agenus in the 4th quarter valued at about $36,000. Apollon Wealth Management LLC boosted its position in shares of Agenus by 25.0% during the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 5,000 shares in the last quarter. Virtu Financial LLC bought a new position in Agenus in the fourth quarter valued at approximately $51,000. Acadian Asset Management LLC bought a new stake in Agenus during the first quarter worth $58,000. Finally, Bank of Montreal Can bought a new position in shares of Agenus in the 4th quarter valued at $69,000. Institutional investors own 61.46% of the company's stock.
Agenus Company Profile
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Recommended Stories
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
